Seek .(US:SKLTY) Xin Lang Cai Jing·2025-09-17 15:00Core Insights - China's innovative drug sector is experiencing explosive growth, with overseas licensing transaction amounts significantly increasing [1] - In the first half of this year, the transaction amount for innovative drug licensing has already exceeded $66 billion, surpassing the total for the entire previous year [1] - The emergence of AI model DeepSeek has drawn global attention, paralleling the advancements in China's biotechnology sector, marking a transition from generic drugs to innovative drugs [1] Industry Developments - Chinese pharmaceutical companies are attracting numerous international collaborations, indicating a shift in the global perception of China's drug innovation capabilities [1] - Notable partnerships include Pfizer's payment of $1.25 billion for the overseas licensing of an innovative drug from 3SBio in May [1] - Major US pharmaceutical companies such as AbbVie, Merck, and Regeneron have signed licensing agreements worth billions with Chinese firms in the first half of this year [1]